Vernalis Initiates Phase I Trial of V81444 for Parkinson’s Disease
cisionwire, 24 August 2011
Vernalis plc today announces it has dosed the first subjects in a Phase I trial of
V81444, its
adenosine A receptor antagonist programme. A receptor antagonists are believed to have advantages over conventional dopaminergic strategies, in that they may be able to help restore motor function in patients with Parkinson’s Disease (PD), without the side effects commonly associated with today’s treatments.